Effect of Metformin Combined with Atorvastatin on Glucose Metabolism in Schizophrenia Patients with Dyslipidemia
Led by Central South University · Updated on 2026-08-03
400
Participants Needed
8
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Schizophrenia is a serious mental disorder linked to significant disability and health risks, including metabolic side effects like weight gain and dyslipidemia caused by antipsychotic medications. This trial investigates how atorvastatin, a cholesterol-lowering drug, affects glucose metabolism in patients with schizophrenia who have dyslipidemia, and whether metformin can help improve these metabolic issues. Researchers aim to understand the impact of statins on blood sugar and insulin resistance and explore metformins potential benefits for these patients.
Participants will be randomly assigned to two groups one receiving atorvastatin 20 mg daily combined with metformin 1000 mg daily, and the other receiving atorvastatin 20 mg daily with a placebo that looks like metformin. The study lasts six months, with follow-up assessments at three and six months. During this time, patients will take their assigned medications daily, and researchers will monitor their glucose metabolism and lipid levels.
Participants will undergo blood tests at baseline, three months, and six months to measure fasting blood glucose, glycated hemoglobin, insulin levels, and lipid profiles. Additional assessments include oral glucose tolerance tests, abdominal ultrasound, and mental health evaluations using standardized scales. The study monitors changes in glucose metabolism and schizophrenia symptoms while tracking safety and treatment adherence over six months.
CONDITIONS
Brief Title
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Research Team
J
Jing Huang
X
Xinyi Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with schizophrenia according to DSM-5 criteria
Stable symptoms and medication regimen for over 3 months, allowing up to two antipsychotic medications
Temporary use of benzodiazepines permitted
Fasting total cholesterol ≥ 5.2 mmol/L, or fasting triglycerides ≥ 1.7 mmol/L, or fasting LDL-C ≥ 3.4 mmol/L
Two fasting blood glucose tests less than 6.1 mmol/L, taken 1 to 4 weeks apart
No expected issues with relocation, transportation, or access to medical care during the study
Informed consent provided by patient and guardian with signed consent form
You will not qualify if you...
Prior diagnosis of diabetes or diabetes-related complications like diabetic ketoacidosis
Liver or kidney dysfunction indicated by elevated liver enzymes or creatinine, or investigator-assessed impairment
Severe gastrointestinal, respiratory, endocrine, hematologic diseases, or metabolic absorption disorders
Recent ischemic heart disease or cerebrovascular events within the past year
History of prolonged QT interval or abnormal ECG findings unsuitable for participation
Active hepatitis B or chronic active hepatitis C infections
Pregnant or nursing women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 6 months
Participants take atorvastatin daily and are randomly assigned to receive either metformin or a placebo daily. They are monitored for glucose metabolism and lipid levels over six months.
Visits at baseline, 3 months, and 6 months for blood tests and assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Long-Term Safety and Tolerability Study of LB-102 in Adults With Stable Schizophrenia Over 52 Weeks
20-Year Follow-up Study on Early Treatment and Relapse Effects in First Episode Psychosis
Study Comparing Two Formulations of Paliperidone Palmitate Injection 3M in Chinese Adults with Schizophrenia
Randomized, Open-label, Multicenter, Multiple-dose Bioequivalence Study
A Phase 2 Study to Assess Safety and Effectiveness of Different Olanzapine Dosing Schedules in Adults with Schizophrenia
Long-term Study of SEP-363856 Tablets for Adults with Schizophrenia to Evaluate Safety and Tolerability
Open-Label Long-Term Study of ML-007C-MA for Adults with Schizophrenia Evaluating Safety and Effectiveness
Phase 1 Study of LY03020 Oral Tablets to Assess Safety, Tolerability, and Pharmacokinetics in Chinese Adults with Stable Schizophrenia or Healthy Volunteers
Evaluating Deep Transcranial Magnetic Stimulation dTMS for Reducing Antipsychotic-Induced Weight Gain in Schizophrenia Effects of Food Cue-Induced Craving in a Randomized, Crossover, Sham-Controlled Trial
Evaluating Brenipatide with Standard Care Compared to Placebo in Adults with Schizophrenia A Double-Blind, Randomized Phase 2 Study
Evaluating Safety and Early Effects of Oral LTX-001 Compared to Placebo in Adults With Worsening Schizophrenia Symptoms
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study.